Study:
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells. It is
not yet known if carboplatin is more effective with or without liposomal doxorubicin in
treating recurrent ovarian epithelial or primary peritoneal cancer.
Purpose:
Randomized phase III trial to determine the effectiveness of carboplatin with or
without liposomal doxorubicin in treating patients who have recurrent ovarian epithelial or
primary peritoneal cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Ovarian Cancer
Peritoneal Cavity Cancer |
Drug: carboplatin
Drug: pegylated liposomal doxorubicin hydrochloride |
Phase 3 |
Verified by
Southwest Oncology Group
June, 2012
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00043082
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States
David S. Alberts, MD., Study Chair